Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 a.m. PT in San Francisco, CA. The event will feature a presentation by management, with a live webcast available on Kodiak's website. The company focuses on developing therapeutics for retinal diseases, leveraging its proprietary ABC Platform™. Kodiak's lead candidate, tarcocimab tedromer, aims to treat conditions like wet age-related macular degeneration and diabetic eye diseases.
Details
News Market Reaction – KOD
The recorded move for KOD in the trading session of this news was +9.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Jan. 4, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time).
A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, tarcocimab tedromer, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including wet age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development. KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases. We are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301712894.html
SOURCE Kodiak Sciences Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.